Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

379
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
379
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

1.6K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.6K
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

344
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
344
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

135
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
135
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

144
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
144
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

767
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
767

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A longitudinal study of ABC transporter expression in canine multicentric lymphoma.

Veterinary journal (London, England : 1997)·2014
Same author

Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma.

Toxicology in vitro : an international journal published in association with BIBRA·2014
Same author

Inhibition of P-glycoprotein by psychotherapeutic drugs in a canine cell model.

Journal of veterinary pharmacology and therapeutics·2014
Same author

Comparing the glucuronidation capacity of the feline liver with substrate-specific glucuronidation in dogs.

Journal of veterinary pharmacology and therapeutics·2013
Same author

Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.

Journal of veterinary pharmacology and therapeutics·2013
Same author

A porcine lymphocyte model for P-gp inhibition studies.

Journal of veterinary pharmacology and therapeutics·2011

Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps
09:30

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Published on: July 19, 2024

2.3K

A functional model for feline P-glycoprotein.

C D van Beusekom1, R Lange1, J A Schrickx1

  • 1Faculty of Veterinary Medicine, Institute for Risk Assessment Sciences, Veterinary Pharmacology, Pharmacotherapy and Toxicology, Utrecht, The Netherlands.

Journal of Veterinary Pharmacology and Therapeutics
|July 21, 2015
PubMed
Summary

This study developed a new assay to test how veterinary drugs affect P-glycoprotein (P-gp) in cats. Some drugs strongly inhibited P-gp, while others had no effect, aiding in safer drug development.

More Related Videos

Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time
08:33

Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time

Published on: March 11, 2021

2.4K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K

Related Experiment Videos

Last Updated: Apr 6, 2026

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps
09:30

Author Spotlight: Exploring Cellular Processes by Modeling Ligands in Cryo-EM Maps

Published on: July 19, 2024

2.3K
Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time
08:33

Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time

Published on: March 11, 2021

2.4K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K

Area of Science:

  • Pharmacology
  • Veterinary Medicine
  • Cell Biology

Background:

  • P-glycoprotein (P-gp), encoded by ABCB1, is a crucial efflux transporter found at biological barriers in various species.
  • Inhibition of P-gp can alter drug pharmacokinetics, potentially causing drug-drug interactions, toxicity, and adverse side effects.

Purpose of the Study:

  • To establish a functional assay for quantifying the inhibitory potential of veterinary drugs on feline P-gp.
  • To assess the inhibitory effects of specific compounds on P-gp activity in a feline lymphoma cell model.

Main Methods:

  • Utilized fluorescence-associated flow cytometry with feline lymphoma cells to measure P-gp function.
  • Employed known P-gp inhibitors and other compounds as controls and test substances.

Main Results:

  • PSC833 and ivermectin demonstrated potent inhibition of feline P-gp.
  • Cyclosporine and verapamil exhibited moderate inhibition of P-gp function.
  • Ketoconazole, itraconazole, diazepam, and its metabolites showed no significant effect on P-gp activity in this model.

Conclusions:

  • The developed functional assay effectively measures the inhibitory potency of drugs on feline P-gp.
  • This assay provides a valuable tool for evaluating the safety and potential drug interactions of new veterinary drugs targeting feline P-gp.